Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

Cancer Screening Molecular Tools

Fengting Yan

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

ASCO® 2023 Summary: "GI Key Studies Including PROSPECT, HERIZON-BTC-…

Insights from 2023 ASCO® Annual Meeting

R. Kim, R. Mehta

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

ASCO GI 2023 Conference Coverage

N. Uboha, A. Turk, K. Spencer, M. Cecchini

Oligometastatic Colon Cancer to Liver: Case Presentation and Panel D…

Integrity CE

V. Lee, R. Kumar, N. Bhagat, E. Winslow

Opus One: Final Results - RFA in Axial Skeleton

Jason Levy

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Sol…

UCSF School of Medicine

H. Kang

Extensive, Liver-Only Metastases From Colon Cancer: Case Presentatio…

Integrity CE

V. Lee, E. Christenson, N. Bhagat, E. Winslow

Year in Review: Hepatobiliary Cancers

Moffitt Cancer Center

R. Kim, T. Biachi

ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib …

Insights from 2023 ASCO® Annual Meeting

V. Subbiah

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Total Health

A. Grothey

Combined Hepatocellular-Cholangiocarcinoma: Diagnosis and Management

Integrity CE

J. Birkness-Gartman

GI Oncology Year in Review: Hepatobiliary Cancers

Yale Cancer Center

P. Kunz

Pemigatinib in Cholangiocarcinoma: Targeting FGFR2 Fusions

Arndt Vogel

MRD in GI Malignancies: Current Clinical Utility of ctDNA

Horizon CME

A. Scott

Updates in Targeted Therapies for Metastatic Biliary Tract Cancers

Integrity CE

J. Harding

ESMO Asia 2023 Insights: "Past, Present & Future Clinical Management…

Insights from 2023 ESMO Asia Annual Meeting

M. Ikeda

ASCO® GI 2024 Insights: "PROOF 301 Trial - Oral FGFR Inhibitor Infig…

Insights from 2024 ASCO® GI Annual Meeting

G. Abou-Alfa